Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor
Sarah Pringle, Bert van der Vegt, Xiaoyan Wang, N. Van Bakelen, T. Jeroen N. Hiltermann, Fred K. L. Spijkervet, Arjan Vissink, Frans G. M. Kroese, Hendrika Bootsma
Abstract
This patient lacked conventional SG acinar cells following anti-PD-L1 therapy and demonstrated presence of hybrid intercalated duct-like structures. Understanding which mechanisms and dynamics underpinning this aberrant parenchyma may be crucial to understand how SG dysfunction post ICI therapy, and potentially other affected organs. Furthermore, although the patient treated with anti-PD-L1 antibody examined here fulfills the criteria for pSS and demonstrated focal lymphocytic sialadentitis, the further histopathological characteristics do not resemble pSS.
Topics & Concepts
DurvalumabSalivary glandMedicineParotid glandPathologyParenchymaImmunohistochemistryDuctal cellsImmune systemAutoantibodySubmandibular glandImmunotherapyAntibodyImmunologyPembrolizumabSalivary Gland Tumors Diagnosis and TreatmentSalivary Gland Disorders and FunctionsCancer Immunotherapy and Biomarkers